Peginterferon alfa-2a: a review of approved and investigational uses (Q35874153)

10 August 2017

1 reference

title

Peginterferon alfa-2a: a review of approved and investigational uses (English)

1 reference

10 August 2017

peginterferon alfa-2a

1 reference

S James Matthews

1

1 reference

PubMed ID

15336466

10 August 2017

Christopher McCoy

series ordinal

2

1 reference

10 August 2017

1 July 2004

1 reference

10 August 2017

Clinical Therapeutics

1 reference

10 August 2017

26

1 reference

10 August 2017

7

1 reference

10 August 2017

991-1025

1 reference

Whence interferon? Variety in the production of interferon in response to viral infection.

10 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Pegylated interferons for the treatment of chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

10-Year follow-up after interferon-alpha therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Pegylation: a novel process for modifying pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Clinical Pharmacokinetics of Interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

A pharmacokinetic model for alpha interferon administered subcutaneously

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Pharmacokinetics of natural human IFN-alpha in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Tolerance and pharmacokinetics of high doses of interferon-alpha-2a in a hemodialysis patient

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Viruses and interferons

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

The interferons. Mechanisms of action and clinical applications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Potential role of immune system activation-associated production of neopterin derivatives in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Viral kinetics in hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Treatment of recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Hepatitis C and progression of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Pegylated interferon and ribavirin-induced interstitial pneumonitis with ARDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Homicidal ideation secondary to interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Reactivation of sarcoidosis during interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

An open-label trial of citalopram for major depression in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Predictors of a favorable response to alpha interferon therapy for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

Early predictors of response to treatment in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990173-7

7 January 2021

10.1016/S0149-2918(04)90173-7

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15336466